Genentech panel advises against Roche's takeover bid

02/23/2009 | Financial Times (free content) · San Francisco Chronicle

A three-member committee of Genentech directors unanimously recommended that shareholders reject Roche's $42 billion buyout bid, saying the offer "substantially undervalues" the biotech company. "We are disappointed that Roche has chosen not to consider an appropriate price range for Genentech's minority shares or to constructively negotiate with our committee, and we must recommend that stockholders not tender their shares as a result," they wrote in a statement.

View Full Article in:

Financial Times (free content) · San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC